Technical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC

Introduction: To assess the technical feasibility and safety of repeated percutaneous computed tomography (CT)–guided transthoracic biopsies and intratumoral injections of gene-modified dendritic cells in metastatic NSCLC. Methods: A total of 15 patients with 15 NSCLC lesions measuring greater than...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Puja Shahrouki, MD, Jay M. Lee, MD, Jonathan Barclay, MD, Sarah N. Khan, MD, Scott Genshaft, MD, Fereidoun Abtin, MD, Steven M. Dubinett, MD, Aaron Lisberg, MD, Sherven Sharma, PhD, Edward B. Garon, MD, Robert Suh, MD
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Dendritic cells Non–small cell lung cancer Gene therapy Immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/cf93339bf11f4025bd759e5634159336
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cf93339bf11f4025bd759e5634159336
record_format	dspace
spelling	oai:doaj.org-article:cf93339bf11f4025bd759e56341593362021-12-02T05:03:47ZTechnical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC2666-364310.1016/j.jtocrr.2021.100242https://doaj.org/article/cf93339bf11f4025bd759e56341593362021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666364321001016https://doaj.org/toc/2666-3643Introduction: To assess the technical feasibility and safety of repeated percutaneous computed tomography (CT)–guided transthoracic biopsies and intratumoral injections of gene-modified dendritic cells in metastatic NSCLC. Methods: A total of 15 patients with 15 NSCLC lesions measuring greater than 1.0 cm underwent two cycles of intratumoral biopsies and CCL21 dendritic cell injections separated by 7 days. All needle placements and injections were done under CT guidance. Clinical and imaging follow-up was done approximately 4 weeks after the first procedure. Safety and feasibility were determined as: (1) safety and feasibility similar to that of single-needle biopsy, and (2) an absence of serious adverse events defined as grade greater than or equal to three according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Results: A total of 30 percutaneous, transthoracic intratumoral biopsies and injections into the lung cancer were performed, two cycles (at d 0 and 7) received by each patient (311 biopsies and 96 intratumoral injections). All percutaneous cases achieved technical success with respect to needle placement for both biopsy and injection of CCL21 dendritic cells. Only minor complications were observed (grade <3), including pneumothorax (n = 10, 33%) and small postbiopsy hemorrhage (n = 2, 7%). Pneumothorax was moderate (n = 1) or trace (n = 9), with resolution of the moderate pneumothorax after manual aspiration without chest tube placement. No patient required chest tube placement. No other complications or serious adverse effects related to the biopsy or dendritic cell injection were noted. All patients were in stable condition after up to 4 hours in the recovery unit and were discharged home on the same day. No procedure-related complications were observed on imaging or clinical follow-up at 4 weeks. Conclusions: Repeated percutaneous, transthoracic CT-guided biopsies and intratumoral gene-modified cell-based immunotherapy injections into lung cancers are technically feasible, safe, and reproducible. There were no procedure-related serious (defined as grade ≥3) adverse events.Puja Shahrouki, MDJay M. Lee, MDJonathan Barclay, MDSarah N. Khan, MDScott Genshaft, MDFereidoun Abtin, MDSteven M. Dubinett, MDAaron Lisberg, MDSherven Sharma, PhDEdward B. Garon, MDRobert Suh, MDElsevierarticleDendritic cellsNon–small cell lung cancerGene therapyImmunotherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJTO Clinical and Research Reports, Vol 2, Iss 11, Pp 100242- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Dendritic cells Non–small cell lung cancer Gene therapy Immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Dendritic cells Non–small cell lung cancer Gene therapy Immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Puja Shahrouki, MD Jay M. Lee, MD Jonathan Barclay, MD Sarah N. Khan, MD Scott Genshaft, MD Fereidoun Abtin, MD Steven M. Dubinett, MD Aaron Lisberg, MD Sherven Sharma, PhD Edward B. Garon, MD Robert Suh, MD Technical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC
description	Introduction: To assess the technical feasibility and safety of repeated percutaneous computed tomography (CT)–guided transthoracic biopsies and intratumoral injections of gene-modified dendritic cells in metastatic NSCLC. Methods: A total of 15 patients with 15 NSCLC lesions measuring greater than 1.0 cm underwent two cycles of intratumoral biopsies and CCL21 dendritic cell injections separated by 7 days. All needle placements and injections were done under CT guidance. Clinical and imaging follow-up was done approximately 4 weeks after the first procedure. Safety and feasibility were determined as: (1) safety and feasibility similar to that of single-needle biopsy, and (2) an absence of serious adverse events defined as grade greater than or equal to three according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Results: A total of 30 percutaneous, transthoracic intratumoral biopsies and injections into the lung cancer were performed, two cycles (at d 0 and 7) received by each patient (311 biopsies and 96 intratumoral injections). All percutaneous cases achieved technical success with respect to needle placement for both biopsy and injection of CCL21 dendritic cells. Only minor complications were observed (grade <3), including pneumothorax (n = 10, 33%) and small postbiopsy hemorrhage (n = 2, 7%). Pneumothorax was moderate (n = 1) or trace (n = 9), with resolution of the moderate pneumothorax after manual aspiration without chest tube placement. No patient required chest tube placement. No other complications or serious adverse effects related to the biopsy or dendritic cell injection were noted. All patients were in stable condition after up to 4 hours in the recovery unit and were discharged home on the same day. No procedure-related complications were observed on imaging or clinical follow-up at 4 weeks. Conclusions: Repeated percutaneous, transthoracic CT-guided biopsies and intratumoral gene-modified cell-based immunotherapy injections into lung cancers are technically feasible, safe, and reproducible. There were no procedure-related serious (defined as grade ≥3) adverse events.
format	article
author	Puja Shahrouki, MD Jay M. Lee, MD Jonathan Barclay, MD Sarah N. Khan, MD Scott Genshaft, MD Fereidoun Abtin, MD Steven M. Dubinett, MD Aaron Lisberg, MD Sherven Sharma, PhD Edward B. Garon, MD Robert Suh, MD
author_facet	Puja Shahrouki, MD Jay M. Lee, MD Jonathan Barclay, MD Sarah N. Khan, MD Scott Genshaft, MD Fereidoun Abtin, MD Steven M. Dubinett, MD Aaron Lisberg, MD Sherven Sharma, PhD Edward B. Garon, MD Robert Suh, MD
author_sort	Puja Shahrouki, MD
title	Technical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC
title_short	Technical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC
title_full	Technical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC
title_fullStr	Technical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC
title_full_unstemmed	Technical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC
title_sort	technical feasibility and safety of repeated computed tomography–guided transthoracic intratumoral injection of gene-modified cellular immunotherapy in metastatic nsclc
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/cf93339bf11f4025bd759e5634159336
work_keys_str_mv	AT pujashahroukimd technicalfeasibilityandsafetyofrepeatedcomputedtomographyguidedtransthoracicintratumoralinjectionofgenemodifiedcellularimmunotherapyinmetastaticnsclc AT jaymleemd technicalfeasibilityandsafetyofrepeatedcomputedtomographyguidedtransthoracicintratumoralinjectionofgenemodifiedcellularimmunotherapyinmetastaticnsclc AT jonathanbarclaymd technicalfeasibilityandsafetyofrepeatedcomputedtomographyguidedtransthoracicintratumoralinjectionofgenemodifiedcellularimmunotherapyinmetastaticnsclc AT sarahnkhanmd technicalfeasibilityandsafetyofrepeatedcomputedtomographyguidedtransthoracicintratumoralinjectionofgenemodifiedcellularimmunotherapyinmetastaticnsclc AT scottgenshaftmd technicalfeasibilityandsafetyofrepeatedcomputedtomographyguidedtransthoracicintratumoralinjectionofgenemodifiedcellularimmunotherapyinmetastaticnsclc AT fereidounabtinmd technicalfeasibilityandsafetyofrepeatedcomputedtomographyguidedtransthoracicintratumoralinjectionofgenemodifiedcellularimmunotherapyinmetastaticnsclc AT stevenmdubinettmd technicalfeasibilityandsafetyofrepeatedcomputedtomographyguidedtransthoracicintratumoralinjectionofgenemodifiedcellularimmunotherapyinmetastaticnsclc AT aaronlisbergmd technicalfeasibilityandsafetyofrepeatedcomputedtomographyguidedtransthoracicintratumoralinjectionofgenemodifiedcellularimmunotherapyinmetastaticnsclc AT shervensharmaphd technicalfeasibilityandsafetyofrepeatedcomputedtomographyguidedtransthoracicintratumoralinjectionofgenemodifiedcellularimmunotherapyinmetastaticnsclc AT edwardbgaronmd technicalfeasibilityandsafetyofrepeatedcomputedtomographyguidedtransthoracicintratumoralinjectionofgenemodifiedcellularimmunotherapyinmetastaticnsclc AT robertsuhmd technicalfeasibilityandsafetyofrepeatedcomputedtomographyguidedtransthoracicintratumoralinjectionofgenemodifiedcellularimmunotherapyinmetastaticnsclc
_version_	1718400676855283712

Technical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC

Ejemplares similares